Full-Time

Manager-Labelling

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Mid, Senior

Hyderabad, Telangana, India

Category
Public Health
Biology & Biotech
Requirements
  • Doctorate degree OR
  • Master’s degree and 4 to 6 years of directly related experience OR
  • Bachelor’s degree and 6 to 8 years of directly related experience OR
  • Diploma and 10 to 12 years of directly related experience
  • Knowledge of Labeling Management Systems (e.g., Veeva Vault) and related document management tools.
  • Strong knowledge of global regulatory labeling requirements, especially for pharmaceuticals or biologics.
  • Proven track record in project planning and execution, with strong organizational and problem-solving skills.
  • Excellent communication skills, with the ability to collaborate effectively in a global, cross-functional environment.
  • Experience in continuous improvement methods to enhance labeling processes and efficiency.
Responsibilities
  • Coordinate end-to-end labeling changes (including updates, reviews, and approvals) ensuring alignment with regional and international regulations.
  • Maintain and refine labeling templates, SOPs, and related documentation to sustain consistency and compliance.
  • Collaborate with local, regional, and global teams—including Regulatory Affairs, Quality, and Supply Chain—to identify labeling requirements, address challenges, and meet project milestones.
  • Communicate clearly and proactively with relevant stakeholders, providing expertise on labeling processes and compliance requirements.
  • Develop detailed project plans and timelines for labeling initiatives, ensuring completion within defined schedules.
  • Monitor progress, identify potential risks, and implement corrective actions to keep projects on track.
  • Identify opportunities to streamline labeling workflows and enhance efficiency, driving continuous improvement within the labeling function.
  • Support inspection readiness by maintaining up-to-date records, robust quality checks, and accurate documentation for audit purposes.
  • Perform critical reviews of artwork, translations, and labeling content to verify accuracy and adherence to regulatory standards.
  • Troubleshoot issues related to labeling systems, ensuring timely resolution and minimal operational disruption.
  • Provide guidance and training to junior team members and new hires on labeling standards, tools, and best practices.
  • Foster a culture of knowledge-sharing and continuous learning to build expertise within the team.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The company's goal is to improve patient care and outcomes by providing effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.